Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy.
Keywords: Contrast-induced nephropathy; Diabetic cardiomyopathy; Myocardial dysfunction induced by anti-cancer drugs; Non-ischemic cardiomyopathy; Sepsis; Trimetazidine.
Copyright © 2017. Published by Elsevier B.V.